• OPA Submission - Regulatory Amendments to Ontario Regulation 202/94 (General) made under the Pharmacy Act, 1991
• OPA Submission – Proposed Regulatory Amendments to Ontario Regulation 329/04 under the Personal Health Information Protection Act, 2004
• Pharmacy Audits by Third-party Payors on ODB Co-payments Submitted During the Ministry's COVID-19 Supply Limit Recommendation
• Reminder: Express Scripts Canada (ESC) Claims Submissions over $9,999.99

• Ask the Customer Experience and Administration Team

• The MASTER Plan for Diabetes Continuing Education Program
• Mastering Injections in Pediatrics
• Providing LGBTQ+ Inclusive Care at Your Pharmacy

• Hospital Coverage Is Provided by Your OPA Secure Health Plan
• Pharmacy Risk Prevention Tips

• DDD Notice No. 20123 Posted July 28, 2020 Prescription Forgery Alert
• DDD Notice No. 20121 Posted July 24, 2020: Notice from the Executive Officer – Monitored Drugs List (MDL) Update Effective: July 24, 2020
• DDD Notice No. 20120 Posted July 24, 2020: ODB Formulary Edition No. 43, Summary of Changes – July 31, 2020
• DDD Notice No. 20119 Posted July 24, 2020 Prescription Forgery Alert

• Status of Ranitidine Drugs in Canada
• Remdesivir Authorized with Conditions for the Treatment of Patients in Canada with Severe COVID-19 Symptoms

• Reminder: Public Consultation on the Regulatory Amendments for Expansion of Scope Closing July 27, 2020
• Non-Insured Health Benefits (NIHB) Program Providers Update
• Concerns, Beliefs and Attitudes of Pharmacists About Cannabis Use Survey
• New Episode of Pharmacists' Matters Available Now

• Ask the Practice Support Network
• Reduced Pricing on Hand Sanitizer for Pharmacy Professionals

• An Update on Direct Oral Anticoagulation
• Managing Your Pharmacy: The Business Essentials
• Board Certified Geriatric Pharmacist (BCGP) Preparation Course – Medication Therapy Management for Older Adults

• Why Students Need Life Insurance
• Dependent Children’s Insurance

• Importation of PTU™ (Propylthiouracil) 50 mg due to Shortage of Canadian Labelled Propylthiouracil 50 mg Products

• DDD Notice No. 20117 Posted July 21, 2020 Prescription Forgery Alert
• DDD Notice No. 20116 Posted July 15, 2020 Prescription Forgery Alert

• Three Lots of Antidiuretic DDAVP Spray Recalled Because of Potential Overdose Risk
• Health Canada Important Safety Information on Methadone Treatment of Opioid Dependence and Potential Risk of Lack of Effect when Switching between Different Products

• ODPRN Ontario Prescription Opioid Tool: Quarterly Update – COVID-19 Insights
• Update from the Canadian Red Cross
• TELUS Health 2020 Health Drug Data Trends and National Benchmarks Report
• CPhA COVID-19 Resource: In-pharmacy Poster for Encouraging Use of Masks

• Ask the Customer Experience and Administration Team

• How to Add Value to the Pharmacy Business as a Pharmacy Technician
• Applying NAPRA's Non-Sterile Compounding Standards Into Practice
• Mastering Injections in Pediatrics

• COSECO Insurance Company unites with Co-operators General Insurance Company
• Do I Need Life insurance?

• DDD Notice No. 20113 posted July 13, 2020 Prescription Forgery Alert
• DDD Notice No. 20112 posted July 9, 2020 Prescription Forgery Alert

• ICYMI: OPA Board Elections
• FINAL REMINDER: UIIP Application Deadline is Friday, July 10
• Updated: OPA’s COVID-19 Insurance Exceptions Tool
• NIHB Program Launches New Claims Processing System and Services via Express Scripts Canada

• Ask the Practice Support Network
• Summer Benefit Reminders for OPA Members

• Pandemic Tips: Return to Work Guidance
• How Can Pharmacists Optimize the Care of Patients with Heart Failure?
• The Right Dose: The Positives and Negatives of COVID-19 Testing in Pharmacies

• Get Your 15% Reduced Driving Refund
• Are You Insured Through Your Employer’s Group Plan for Long-Term Disability (LTD)?

• Use of the Drug Picato May Increase the Risk of Skin Cancer
• Recall of Certain Hand Sanitizers That May Pose Health Risks
• Certain Vials of Fertility Drug Cetrotide Recalled Because of Potential Contamination
• Counterfeit Respirators

• ICYMI: Regulations Posted for Consultation to Allow Pharmacists to Perform Point-Of-Care Tests
• Updated: COVID-19 Resources and Tools
• Hand Sanitizers Available to Pharmacies for Resale to Public
• UIIP Deadline of July 10 is Fast Approaching
• Express Scripts Canada – Transition to New Claims Processing System
• ICYMI: New Podcast Released - LGBTQ+ Care in Pharmacy

• Ask the Customer Experience and Administration Team
• OPA Conference 2020 Survey Draw Winners

• Pandemic Tips: Opioid Agonist Therapy

• OPA Professional Liability — Extended Reporting Period
• OPA Store Insurance Renewal 2020 - 2021

• DDD Notice No. 20109 Posted June 29, 2020 Prescription Forgery Alert
• DDD Notice No. 20108 Posted June 26, 2020 Health Network System (HNS) and Narcotics Monitoring System (NMS) Outage Notification to Ontario Drug Programs Agencies
• DDD Notice No. 20107 posted June 24, 2020 Introducing SADIE 2.0 – Now With Designates!

• Recall of Certain Hand Sanitizers That May Pose Health Risks
• Health Product InfoWatch – June 2020
• Recall of Certain Hand Sanitizers That Contain Technical-Grade Ethanol
• NARDIL (Phenelzine Sulfate) Shortage

• ICYMI: Call for OPA Committee Members
• New Podcast Episode Released: LGBTQ+ Care in Pharmacy
• Updated: COVID-19 Resources and Tools
• Patented Medicine Prices Review Board (PMPRB) Draft Guidelines Consultation
• OPA's First Virtual Annual General Meeting and Open Forum

• Ask the Practice Support Network
• Reminder: Nominate a Candidate for the Bowl of Hygeia

• Complimentary Live Webcast on June 24: The Positives and Negatives of COVID-19 Testing in Pharmacies
• Online Program Registration Now Open: Providing LGBTQ+ Inclusive Care At Your Pharmacy
• Pandemic Tips: Pharmacy Technician’s Role in Supporting Patients and Pharmacy During the Pandemic

• Business Expense Disability Insurance

• DDD Notice No. 20104 posted June 22, 2020 Prescription Forgery Alert
• DDD Notice No. 20105 posted June 22, 2020: ODB Formulary Edition No. 43, Summary of Changes June 30, 2020
• DDD Notice No. 20106 posted June 23, 2020 Prescription Forgery Alert

• Health Canada Drug Shortages Updates, June 17, 2020
• Health Canada Drug Shortages Updates, June 18, 2020

• Recall of Certain Hand Sanitizers That May Pose Health Risks
• Important Safety Information on MabCampath (alemtuzumab) – Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis - Sanofi-Aventis Canada Inc.

• ICYMI: Regulatory Amendments for Expansion of Scope Posted for Public Consultation
• ICYMI: Removal of the Ministry’s 30-days’ Supply Dispensing Limit Recommendation
• ICYMI: Message From OPA's CEO: Our Commitment to Create a Diversity Task Force
• Updated: COVID-19 Resources and Tools
• Extension of Red Cross First-Aid Certification

• All OPA Awards Except Bowl of Hygeia Moved to 2021
• Ask the Customer Experience and Administration Team

• Pandemic Tips: Leveraging Mobile Apps in Pharmacy During COVID-19

• Is Protecting Your Family and Business a Priority?
• ICYMI: Get Your Reduced Driving Refund

• DDD Notice No. 20102 posted June 12, 2020 Executive Officer Notice: Removal of the 30-days' Supply Dispensing Limit Recommendation

• Health Canada Drug Shortages Updates, June 15, 2020
• Health Canada Drug Shortages Updates, June 16, 2020

• Certain Metformin Diabetes Drugs Recalled Due to the Presence or Possible Presence of NDMA
• Risk of Poisoning From Hand Sanitizers Sold in Beverage Containers

• Pharmacist’s Role in Managing Opioid Use Disorder During COVID-19
• External Research Initiatives and Resources

• Ask the Practice Support Network
• OPA’s Newest Member Benefit Partner, Relief Buddy
• Complete OPA's Conference Survey for a Chance to Win a Prize

• Pandemic Tips: Leveraging Mobile Apps in Pharmacy During COVID-19

• Professional Liability Insurance Claims Reporting

• DDD Notice No. 20100 Posted June 4, 2020 Prescription Forgery Alert

• Recall of Certain Hand Sanitizers That May Pose Health Risks